UGT2B15抗体;UGT2B15 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12916(UGT2B15 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The UGT2B15 antibody is a crucial tool for studying the UDP-glucuronosyltransferase 2B15 (UGT2B15) enzyme, a member of the UGT superfamily responsible for phase II drug metabolism. UGT2B15 catalyzes the glucuronidation of endogenous compounds (e.g., steroids, bile acids) and xenobiotics, enhancing their water solubility for excretion. This enzyme is highly expressed in the liver, prostate, breast, and other steroid-sensitive tissues, where it modulates the bioavailability and activity of hormones like androgens and estrogens. Dysregulation of UGT2B15 has been implicated in hormone-dependent cancers (e.g., prostate, breast) and metabolic disorders, making it a target for therapeutic research.

UGT2B15 antibodies are typically raised in rabbits or mice using peptide antigens derived from conserved regions of the human protein. They enable the detection and quantification of UGT2B15 expression via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validated antibodies are essential for investigating tissue-specific expression patterns, enzyme localization, and regulatory mechanisms in disease models. Commercial antibodies often undergo specificity testing using knockout cell lines or siRNA knockdown to ensure minimal cross-reactivity with homologous UGT isoforms like UGT2B17.

These antibodies are widely used in pharmacokinetic studies, cancer biology, and toxicology to explore interindividual variability in drug metabolism and hormone homeostasis. Researchers rely on them to elucidate UGT2B15's role in drug resistance, endocrine signaling, and personalized medicine approaches.